Given the efficacy of RTG in animal models of neonatal epilepsy caused by KCNQ2 mutations, potassium channel openers should be considered as a therapeutic option for BFNE/BNE and perhaps even for EOEE. The gene discussed is KCNA3; the disease is epilepsy.